Yahoo
NYSE - Delayed Quote USD

Evolent Health, Inc. (EVH)

4.3000 +0.0500 (+1.18%)
At close: 4:00:02 PM EDT
4.3000 0.0000 (0.00%)
After hours: 4:01:27 PM EDT
Trade EVH on Coinbase
Chart Range Bar
Loading chart for EVH
  • Previous Close 4.2500
  • Open 4.2600
  • Bid 4.1000 x 320000
  • Ask 4.4800 x 110000
  • Day's Range 4.0850 - 4.3100
  • 52 Week Range 2.0950 - 6.8900
  • Volume 1,145,830
  • Avg. Volume 2,541,521
  • Market Cap (intraday) 486.155M
  • Beta (5Y Monthly) 1.02
  • PE Ratio (TTM) --
  • EPS (TTM) -4.4900
  • Earnings Date Nov 5, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 5.75
  • Zacks Rating Neutral

Evolent Health, Inc., through its subsidiary, provides specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company offers integrated value-based care platform for health plan administration and management. It also provides administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients. In addition, the company provides Machinify Auth Intelligence, an artificial intelligence tool to aid nurses and physicians in completing clinical review of prior authorization requests. Evolent Health, Inc. was founded in 2011 and is headquartered in Arlington, Virginia.

www.evolent.com

4,200

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

EVH
7.50%
S&P 500 (^GSPC)
10.73%

1-Year Return

EVH
34.85%
S&P 500 (^GSPC)
11.11%

3-Year Return

EVH
82.17%
S&P 500 (^GSPC)
81.91%

5-Year Return

EVH
85.31%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 652.52M
Earnings -28.36M
Profit Margin -4.35%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-400M
-200M
0
200M
400M
600M
-80.0%
-60.0%
-40.0%
-20.0%

Analyst Insights

View More

Analyst Price Targets

3.00 Low
5.75 Average
4.3000 Current
8.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/18/2026
Analyst JP Morgan
Rating Action Maintains
Rating Overweight
Price Action Raises
Price Target 5 -> 6

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -24.08%

  • Return on Assets (ttm)

    -0.79%

  • Return on Equity (ttm)

    -66.97%

  • Revenue (ttm)

    2.1B

  • Net Income Avi to Common (ttm)

    -511.06M

  • Diluted EPS (ttm)

    -4.4900

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    115.7M

  • Total Debt/Equity (mrq)

    253.23%

  • Levered Free Cash Flow (ttm)

    126.85M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: